Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil<sup>®</sup>) in C26 Tumor-Bearing Immunocompetent Mice

Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil<sup>®</sup>) in C26 Tumor-Bearing Immunocompetent Mice

Doxorubicin (DXR) has been reported to have direct cytotoxicity against cancer cells and indirect immunotoxicity by modulation of host antitumor immunity. Hence, it may prevent cancer progression by a dual mechanism. Doxil<sup>®</sup>, a formulation of DXR encapsulated in polyethylene gl...

Full description

Bibliographic Details
Main Authors: Takuma Takayama, Taro Shimizu, Amr S. Abu Lila, Yuki Kanazawa, Hidenori Ando, Yu Ishima, Tatsuhiro Ishida
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceutics
Subjects:
antitumor immunity
chemotherapy
doxorubicin (DXR)
drug delivery system
Doxil<sup>®</sup>
Online Access:https://www.mdpi.com/1999-4923/12/10/990

Internet

https://www.mdpi.com/1999-4923/12/10/990

Similar Items